<DOC>
	<DOCNO>NCT01100775</DOCNO>
	<brief_summary>Schizophrenia chronic disorder onset psychosis occur late teen early twenty , cognitive impairment negative symptom frequently emerge much earlier . Such cognitive impairment negative symptom much milder also observe high-risk group ( relative schizophrenia patient ) , may may develop full blow psychotic disorder . Our study plan recruit non-ill subject test effect galantamine clinical/physiological/cognitive measure . This study serve several goal : If drug find effective treating subtle deficit , provide treatment strategy individual schizophrenia spectrum personality disorder early intervention schizophrenia . In addition , one difficulty test drug schizophrenia patient take medication ( i.e. , antipsychotic drug ) change effect test drug . The propose study subject take antipsychotic medication . Our study carry two session , least one month apart . Subjects randomly assign two possible order administration : drug placebo , placebo drug . Subjects give lead-in 3 day 4mg/ twice day galantamine ( placebo ) follow 8 mg ( placebo ) 4th day , day test . We administer battery clinical/cognitive/neurophysiological test 8 mg drug dose .</brief_summary>
	<brief_title>Effects Galantamine Cognition</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>age range 1864 ( confirm driver license form identification ) presence 3 SSP symptom ( least 2 SSP symptom negative symptom define schizoid trait ) presence visuospatial work memory impairment define error oculomotor delay response ( ODR ) task 0.5 SD mean value healthy control subject relative individual schizophrenia , schizoaffective disorder , schizophreniform disorder able provide write informed consent ( ESC score 10 ) subject meet criterion lifetime diagnosis one DSM IV , Axis I psychotic disorder ( exception single past episode major depressive disorder psychotic feature psychotic symptom associate substance abuse substance abuse end 6months prior study participation ) ( SSP recruitment ) subject meet DSMIV criterion current alcohol substance dependence ( nicotine ) within last 6 month DSMIV criterion alcohol substance abuse ( nicotine ) within last month medical condition preclude participation drug trial assessments outcome measure ( include significant brain , cardiac , liver , lung , endocrinological metabolic disorder ) receive investigational drug precede four week pregnant childbearing age use medically approve form birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Galantamine</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>work memory</keyword>
	<keyword>cognitive</keyword>
</DOC>